PAMS
VRDN icon

Pictet Asset Management (Switzerland)’s Viridian Therapeutics VRDN Stock Holding History

Pictet Asset Management (Switzerland)’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		$25.3M Buy
1,061,517
+18,552
+2% +$476K 0.03% 413
2023
Q1 		$26.5M Buy
+1,042,965
New +$33.4M 0.03% 396

Other funds holding VRDN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return

Pictet Asset Management (Switzerland)'s VRDN Position: Q2 2023 in Review

Pictet Asset Management (Switzerland) increased its Viridian Therapeutics (VRDN) stake by 1.8% in Q2 2023, buying an estimated $476K and bringing the position to 1,061,517 shares worth $25.3M. The position accounts for 0.03% of the portfolio, ranked #413.

Pictet Asset Management (Switzerland) first reported a position in VRDN in Q1 2023 and has held it in 2 quarters since. The position peaked at $26.5M in Q1 2023. 128 funds tracked by Wall St. Rank hold VRDN as of Q2 2023.

  • Pictet Asset Management (Switzerland) held 1,061,517 shares of Viridian Therapeutics worth $25.3M as of Q2 2023.
  • Pictet Asset Management (Switzerland) bought 18,552 Viridian Therapeutics shares in Q2 2023, an estimated $476K.
  • Viridian Therapeutics made up 0.03% of Pictet Asset Management (Switzerland)'s portfolio in Q2 2023, its #413 holding.
  • Pictet Asset Management (Switzerland) first reported a position in Viridian Therapeutics in Q1 2023 and has held it in 2 quarters since.
  • Pictet Asset Management (Switzerland)'s Viridian Therapeutics position peaked at $26.5M in Q1 2023.
  • 128 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2023.

Based on Pictet Asset Management (Switzerland)'s 13F filing for Q2 2023, filed 10 Aug 2023.